Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 1998

View Archived Issues

Targeted cytotoxic LHRH analogues show potential as Rx for breast cancer

Dynavax and Vical crosslicense DNA immunization technology

Company Profile: Penwest

Glaxo Wellcome's R&D pipeline remains full and diverse

Genzyme Molecular Oncology, Schering-Plough collaborate to make gene therapy a reality

Novel antifungal peptides isolated by Hoechst Marion Roussel

Vertex describes new MDR-modulating and neuritogenic agents

HIV protease inhibitor research continues at DuPont Merck

Boehringer Ingelheim develops new antiplatelet agents

BMS claims new beta3-adrenoceptor agonists

Antiviral agents that inhibit virus-host cell fusion pursued by Lilly

Duphar presents new vitamin D analogues

Antiprogestational agents with reduced antiglucocorticoid activity claimed by HHS

Hemodynamic profile of new K+ channel activator

Selective inhibitor of PDGF receptor autophosphorylation from Kirin Brewery

New chelating agent developed by Israeli researchers

Pharmacological profile of broad-spectrum, nonopioid analgesic described by Abbott

Novel antitumor cyanoguanidines with good oral bioavailability

Novel coronary artery disease gene therapy scheduled to enter clinical trials

PDMP analogues studied for malaria inhibition

Potential target for a malaria vaccine identified

Johns Hopkins researchers synthesize antimalarial drug candidates

European filing announced for Savedar (DepoCyt)

Malaria vaccine research under way at Gryphon Sciences

Antischistosomal agent derived from myrrh tested in humans

AHP and SKB to merge?

Combination HCV therapy receives priority classification from FDA

Pfizer to develop Nastech formulation of sleep aid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...